PharmaTimesOriginal article
Axoltis reports positive phase 2 data for NX210c
Phase 2positiveNX210cPositive
AI Analysis
Summary
Axoltis reported positive Phase 2 data for NX210c in ALS, demonstrating reduced disease decline and blood-brain barrier target engagement.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Reduced ALS decline and BBB target engagement demonstrated
Importance:7/10
Sentiment:
0.80
ALSPhase 2positive dataBBB penetrationneurology
Related Companies
Read the original article
Published by PharmaTimes on September 21, 2026 11:30 AM